NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/19/2024
Back to search
Official data from USPTO
NANT CANCER VACCINE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NANT CANCER VACCINE
ST13
US500000097800703Class
44
Filing
97800703
Registration
7573522
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
11/19/2024
Trademark type
Word
Nice classes
44
Filing date
02/17/2023
Registration date
11/19/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/19/2024
Last transaction
11/19/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
07/19/2022
First use in commerce
07/19/2022
Drawing code
4
Owner type
16
Owner location
Culver City, CA
Examiner
ALTREE, NICK
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Nant Holdings IP, LLC
Representatives
Michael J. McCue LEWIS ROCA ROTHGERBER CHRISTIE LLP
Technical classification
Nice Classes
Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 44
medical services; medical information; providing a website featuring medical information in the fields of immunotherapy; providing a website featuring medical information in the fields of oncologycancerimmuneoncologyautoimmune diseasesinfectious diseaseshuman diseasesanimal diseasesvaccines biologicscells and cell-derived preparations; providing medical and health information relating to pharmaceuticalsoncologycancerimmuneoncologyimmunotherapyautoimmune diseasesinfectious diseaseshuman diseasesanimal diseasesvaccinesbiologicscellscell-derived preparations
Publications
History of USPTO decisions and trademark events.
35 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
11/19/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/15/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/15/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/15/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/15/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/04/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
07/22/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
07/22/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/22/2024
GNRT
NON-FINAL ACTION E-MAILED
04/22/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
04/22/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/19/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/19/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/03/2024
IUAF
USE AMENDMENT FILED
04/01/2024
EISU
TEAS STATEMENT OF USE RECEIVED
04/01/2024
EX1G
SOU EXTENSION 1 GRANTED
04/01/2024
EXT1
SOU EXTENSION 1 FILED
04/01/2024
EEXT
SOU TEAS EXTENSION RECEIVED
04/01/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/08/2023
PUBO
PUBLISHED FOR OPPOSITION
08/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/19/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/29/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
06/29/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/29/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
06/29/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/29/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/29/2023
GNRT
NON-FINAL ACTION E-MAILED
06/29/2023
CNRT
NON-FINAL ACTION WRITTEN
06/29/2023
DOCK
ASSIGNED TO EXAMINER
06/29/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/08/2023
NWAP
NEW APPLICATION ENTERED
02/21/2023
Continuous trademark protection
Get notified about every new filing that threatens NANT CANCER VACCINE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.